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ABSTRACT: The enormous global burden of neurological and neurodegenerative diseases compels a frantic search for novel 
neurotherapeutics that will address the underlying pathologies, unlike most of the current pharmacological interventions that 
predominantly merely relieve symptoms of disease. A major challenge, however, is that the central nervous system (CNS), in 
contrast to most other well-studied systems, exhibits significant complexity that perhaps makes it one of the, if not the, least 
tractable to date, at least on the drug discovery landscape. Nevertheless, in the last few years, giant strides in CNS research have 
yielded significantly-improved understanding of the molecular underpinnings of the various pathological conditions of the brain, 
not least those associated with the death of neurones, including Parkinson’s and Alzheimer’s diseases. Accordingly, one pathway 
now known to be majorly involved in the induction of neuronal death is associated with the nuclear enzyme, poly (ADP-ribose) 
polymerase-1 (PARP-1), whose excessive activation generates a large amount of its polymer, poly (ADP-ribose) (PAR), which, in 
turn, causes an otherwise beneficial protein, normally resident in the mitochondria, the apoptosis-inducing factor (AIF), to exit 
its natural domain and enter the nucleus, where it causes large-scale DNA fragmentation and chromatin condensation, ultimately 
resulting in neuronal death. This review briefly explores the pathological cascade and suggests why targeting it in drug discovery - 
especially at the level of nuclear AIF translocation - is a rational and promising approach that may eventually deliver novel drugs 
for clinical use. In addition, the work illustrates how a clear knowledge of the spatio-temporal dynamics of molecular events is 
highly critical and, in fact, indispensable to a successful drug discovery and development campaign from the bench to the bedside, 
while at the same time highlighting the multi-disciplinary nature of the drug discovery enterprise.   
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THE PHENOMENON OF CELL DEATH 
In a sense, part of the homeostatic roles of the body is to 
carefully maintain a useful balance between the number of cells 
that are produced and the number of those that are destroyed, 
consistent with the need for a healthy performance of its expected 
physiological functions. It is known that in the early stages of 
embryonic development, especially of the mammalian organism, a 
prodigious number of cells, well in excess of what may be 
eventually required, is produced, followed by the necessary 
physiological sculpting that eliminates the surplus, through 
genetically-programmed cell death, once the various systems, 
including the nervous system, have been established (Cory et al., 
2003). In the mature organism, a disruption of the somewhat-
delicate balance causing a net availability of more cells or less cells 
than needed for proper functioning at any particular time could 
result in pathological scenarios leading to the establishment of 
disease. For example, in cancer, there is an abnormally-excessive 
proliferation of cells due to the loss of normal cell-cycle control on 
the aberrant cells. On the other hand, several acute neurological 
and chronic neurodegenerative conditions of the CNS are 
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characterised by abnormal and significant death of functional 
neurones, and because these lost neurones are not being replaced, 
the functions they serve in the brain (or in the spinal cord) are also 
lost.  
The CNS as we know it is very complex, and it has been the 
preoccupation of scientific research to understand why, how and 
even where cells die in pathological conditions such as stroke, 
Parkinson’s disease and Alzheimer’s disease. It should be promptly 
said that although the remit of this review is to examine a 
particular cell death paradigm in the context of the CNS, the 
phenomenon of cell death, or even the cell death modality being 
considered here, is not unique or restricted to the nervous system. 
Devotion to cell death research is rather, relatively, a mature 
research focus which has seen giant leaps, especially with the 
advent of excellent experimental tools to examine the molecular 
mechanisms that underlie the predisposition of a neurone to injury, 
dysfunction and ultimate demise.  
In line with the frantic investigations, there has been a flurry of 
names, perhaps of nicknames too, describing the different types of 
cell death that have been observed, based on morphological, 
biochemical, enzymological and immunological  features, 
considered in isolation or in combination. So several and diverse 
were the names being churned out with notable speed that the 
Nomenclature Committee on Cell Death recently attempted to rein 
the frenzy by establishing recommendations for describing cell 
death modalities, and it now appears that the use of more precise 
biochemical characteristics (molecular definitions) to describe cell 
death subroutines has the pride of place (Galluzzi et al., 2012; 
Kroemer et al., 2005; Kroemer et al., 2009). Perhaps the study of cell 
death is one current area of scientific investigation that has 
witnessed an exceptional level of semantic confusion as regards the 
choice of an apt name to distinguish any observed death paradigm 
from the other possibilities. This is not surprising, however, as it is 
often the case that any scenario of cell death could manifest 
attributes of the different known paradigms to different degrees, 
with the most prominent feature(s) determining the eventual 
nomenclature.   
Just to mention but a few of the cell death modalities, 
apoptosis, as dubbed by Kerr nearly 40 years ago (Kerr et al., 1972), 
represents an active form of cell death that is highly regulated, 
hence the other name “programmed cell death” that is commonly 
reckoned as synonymous with it, albeit incorrectly, strictly 
speaking, as other forms of cell death are also now known to be 
somewhat regulated, including necrosis, a passive form of cell 
death that was initially conceived as rather largely random, often 
accompanied by cell swelling and the disruption of the cell 
membrane (Lorenzo et al., 2007). One major distinguishing feature 
of apoptosis as observed over the years is its requirement, in most 
cases, for the recruitment of cysteine proteases, called caspases, for 
execution of cell death, from initiation to consummation. Further 
in the cell death arena, autophagy is regarded in some circles as a 
form of cell death (autophagic cell death) but in some others as an 
adaptive stress response which enables the cell to delay its “doom” 
– intracellular materials are degraded and macromolecular entities 
are recycled (Debnath et al., 2005; Galluzzi et al., 2012; Klionsky et al., 
2010). The distinguishing features of apoptosis, necrosis and 
autophagy were recently described (Wang et al., 2009a). Besides, as 
the field currently stands, some other forms of modalities are 
regarded as atypical, and it is certainly a long list – Wallerian 
degeneration, entosis, anoikis, entosis, necroptosis, pyroptosis, 
paraptosis, pyronecrosis and cornification, etc (see (Galluzzi et al., 
2012; Kroemer et al., 2009)).  
Notably, the nature of cell death can be dependent on factors 
such as the type of insult, its degree and duration, and the cellular 
context in which injury is engendered by the insult. It is beyond 
the intent of this review to treat these concepts or cell death types 
in detail, as a number of relevant literature provides in-depth 
coverage. At this point, however, it is worthy of mention that a 
potential avenue of investigation that may attain prominence in the 
future is the elucidation of critical cross-talks that may exist 
among the cell death types and how such inter-relationships, if 
present and of some significant functional consequence, can be 
usefully exploited for novel therapeutics development. To illustrate 
this potential using the example of a likely interplay between 
apoptosis and necrosis, it has been suggested that when energy 
levels within injured cells are too low, they cannot proceed to 
death through apoptosis, which requires energy for execution, and 
therefore may seek an alternative but feasible route for their 
demise, such as necrosis, which could occur despite low cellular 
energy levels. 
POLY (ADP-RIBOSE) POLYMERASE (PARP)-
DEPENDENT CELL DEATH – YET ANOTHER TYPE? 
 The story of PARP illustrates beautifully the consequences of 
the biphasic capabilities of an important cellular enzyme, and how 
what is ideally a beneficial biological entity can unfortunately 
invoke harm in its attempt to remedy a situation that threatens to 
go out of hand. PARP is a protein normally resident in the nucleus, 
with recognised physiological roles in the maintenance of cellular 
homeostasis and genomic stability, among other functions (Smith, 
2001). Actually, PARP is a collective name for a group of about 17 
nuclear proteins that share significant homology and enzymatic 
roles, but to date, one of them, PARP-1 (EC 2.4.2.30) (116-kDa) is 
the most relevant (Hong et al., 2004), for a reason that will soon be 
discussed. Other appellations occasionally used for the PARP 
enzyme include poly (ADP-ribose) synthetase or poly (ADP-
ribose) transferase.  
When a DNA base excision occurs, PARP acts as the sensor for 
the DNA strand nicks and breaks and thus facilitates repair. The 
activated PARP, whose activity increases about 500-fold, does this 
by synthesising its polymer, poly (ADP-ribose) (PAR), which has 
the capacity to attach itself, through a post-translational process 
called ribosylation, to several nuclear proteins (histones, 
topoisomerases I and II, DNA polymerases, DNA ligase-2, high-
mobility-group proteins, transcription factors, etc) and even to 
PARP (Shall et al., 2000; Smulson et al., 2000). Because PARP-1 
synthesises more than 95% of the entire PAR polymer, it is 
adjudged to be the most important of the PARPs, and consequently 
is the most-widely studied (Dawson et al., 2004). Thus, henceforth 
in this review we shall refer to PARP-1, although the potential 
significance of contributions from other PARP isoforms is 
becoming increasingly explored. PARP-1 is highly conserved 
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among eukaryotes (Virag et al., 2002) and features three major 
domains, an N-terminal domain with two zinc finger motifs plus a 
nuclear localisation sequence responsible for DNA-binding, a 
central auto-modification domain, and a C-terminal catalytic 
domain housing the nicotinamide adenine dinucleotide (NAD)-
binding site and the PAR-synthesising domain (Hong et al., 2004; 
Kameshita et al., 1984). 
Nature in its smartness seems to have provided a regulatory 
enzyme, poly (ADP-ribose) glycohydrolase (PARG), which 
controls PAR levels, following synthesis by PARP-1, through 
catalytic (hydrolytic) degradation to free adenosine diphosphate 
(ADP)-ribose units (Davidovic et al., 2001; Whitacre et al., 1995). 
PARG is encoded by a single gene and localises to the nucleus, but 
has alternatively-spliced isoforms with diverse patterns of 
localisation (Bonicalzi et al., 2003; Haince et al., 2006; Meyer-Ficca et 
al., 2004; Meyer et al., 2007). PARG’s PAR-clearing function has 
been shown to be directly relevant to PARP-1-mediated cell death, 
having been found to protect against cell death mediated by the 
PAR polymer (Andrabi et al., 2006) or other stimuli inducing 
PARP-1-dependent cell death (Blenn et al., 2006; Cozzi et al., 2006), 
an observation that further lends credence to the idea that 
regulating the levels of PAR is highly critical to ensuring protection 
against the cell death. 
 
In a situation where DNA damage is mild, PARP-1 activation 
leads to repair, but when damage is profound, PARP-1 becomes so 
over-activated that it produces an exceptionally large amount of 
the PAR polymer that then begins to contribute to cellular damage 
and death (Figure 1 shows the time-dependent accumulation of 
PAR polymer following neuronal challenge with NMDA, which 
induces robust activation of PARP-1. No detectable levels of the 
polymer were observed in neurones lacking PARP-1). Interestingly, 
the cell death elicited by PARP-1 overactivation is unique, although 
some years back it was mistaken for necrosis (Ha et al., 1999), 
perhaps due to some features it exhibits that are similar to those of 
necrosis. In contrast to apoptosis, PARP-1-mediated cell death is 
largely independent of the recruitment of caspases (Yu et al., 2002), 
does not involve formation of apoptotic bodies, and precipitates 
large-, rather than small-scale, DNA fragmentation (Wang et al., 
2009a). Although it also involves the loss of membrane integrity, it 
does not bring about cell swelling, unlike necrosis (Wang et al., 
2004; Yu et al., 2002). 
PARP-1-DEPENDENT CELL DEATH: BIOCHEMICAL 
NATURE, CONTEXT AND PLAYERS  
As mentioned earlier, the process that leads to PARP-1-
dependent cell death begins by the excessive activation of the 
nuclear enzyme, induced by exposure of cells to a severe insult that 
causes appreciable DNA damage. The sequence of biochemical 
events then proceeds through the accumulation of excessive levels 
of the PAR polymer that could induce membrane potential 
dissipation, mitochondrial depolarisation and further downstream 
pathological events culminating in death, as discussed later. This 
process occurs in most mitotic and post-mitotic cells in 
mammalian organisms, occasioned by many different (sources of) 
toxic insults, including glutamate (especially NMDA) receptor 
overactivation (in neurones), oxidative stress, nitrosative stress, 
ischaemia, hypoxia, hypoglycaemia, inflammation and DNA 
alkylation (Fatokun et al., 2008; Pacher et al., 2008; Stone et al., 2002; 
Zhang et al., 1994), and relevant to a myriad of diverse pathological 
situations, including neurological conditions (e.g., stroke and 
traumatic brain injury), neurodegenerative diseases (e.g., 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and 
amyotrophic lateral sclerosis (Lou Gehrig’s disease, especially in 
American parlance)), diabetes, arthritis and liver toxicity (see 
(Dawson et al., 2004; Virag et al., 2002)). So central now in our 
current understanding of this cell death paradigm is the role of 
PAR that a world-class group of investigators has named it 
“parthanatos” (a bonus to Greek mythology enthusiast?). It is a 
marriage of two words, “par,” for the poly (ADP-ribose) polymer, 
and “thanatos,” the personification of death in Greek mythology 
(Andrabi et al., 2008; Harraz et al., 2008).  
Various lines of argument have been adduced in an attempt to 
explain the exact mechanisms involved when cells die at the hands 
of PARP-1 following its overactivation. Historically, the depletion 
of NAD+ that follows PARP-1 overactivation causes the affected 
cells to seek replenishment for the all-important co-factor in order 
to maintain normal cellular metabolic processes. Unfortunately, 
however, this drive for replenishment is an energetically-expensive 
process, since ATP is needed to produce NAD+. It is then 
conceivable that over time the cells become starved of ATP and so 
will have to suffer an inevitably suicidal fate (hence the name 
“suicide hypothesis”), but through a cell death process that does 
not require the maintenance of a significant energy level, which in 
this case is necrosis and not apoptosis (Berger et al., 1986; Ha et al., 
1999). Well, as logical and attractive as this school of thought may 
be, it remains to be conclusively determined whether energy 
depletion plays a major causative role in PARP-1-mediated cell 
death, although arguments abound both against and in favour of it, 
and some latest renaissance in examining the role of bioenergetics 
in cell death may demand a re-think of the current convictions (Liu 
et al., 2009; Sasaki et al., 2009; Yang et al., 2007). In part, the 
FIGURE 1 NMDA induces PARP-1 overactivation and PAR 
synthesis and accumulation in primary cortical neurones. Western 
blot analysis using anti-PAR antibody; Exposure of wild-type (WT) 
cortical neurones to the NMDA receptor agonist, NMDA (500 µM, 5 
min), causes excessive stimulation of the receptor and overactivation of 
PARP-1, leading to time-dependent accumulation of PAR polymer that 
peaks after about 1 h, whereas no detectable levels of the polymer were 
found when cortical neurones from PARP-1 knockout (PARP-1 KO) 
animals were similarly treated, indicating that activation of PARP-1 is 
responsible for PAR synthesis and accumulation. Figure reproduced 
from (Yu et al., 2002) by permission from the American Association for 
the Advancement of Science (AAAS). 
Fatokun             Apoptosis-inducing factor in neuronal death          Biokemistri 23(3):98-107 
101 
weakness of the suicide hypothesis relates to its apparent lack of 
explanation for why it takes so long after the NAD+ has been 
depleted before the cells (neurones in our case) eventually die. 
Another assault against the hypothesis comes from observations in 
PARP-1 knockout mice that their energy stores (levels) following 
focal ischaemic injury are no different from those of their wild-type 
counterparts, despite the fact that their infarct volumes are smaller 
(Goto et al., 2002). These and other grounds for disputation have 
informed the current quest to look further afield for potential 
mediators that may be “fit for purpose” in delineating the 
molecular mechanisms underpinning PARP-1-mediated cell death. 
APOPTOSIS-INDUCING FACTOR (AIF) AS A 
CREDIBLE MEDIATOR OF PARP-1-DEPENDENT 
CELL DEATH 
There is now a compelling weight of evidence supporting the 
responsibility of the mitochondrial flavoprotein, AIF (Susin et al., 
1999), for mediation of PARP-1-dependent cell death. Again, the 
name that this protein still bears is a vivid reflection of how 
progressive scientific understanding could, and should, be, in an 
attempt to explore a biological target with previously unknown 
function(s). No one would have called this protein AIF if we had 
the knowledge about it when it was first christened as we do 
today, since it’s been clearly shown that the protein does not 
induce classical apoptosis, unlike previously thought. Anyway, 
perhaps for the mere purpose of avoiding any confusion likely to 
arise from a re-christening, this molecule has been fated to bear 
“guilt by nomenclature” for a crime there is no convincing evidence 
it ever commits. The AIF gene is on chromosome X (Susin et al., 
1999), synthesised in the cytoplasm (67 kDa) before its importation 
into the mitochondria where it is processed to a mature 62-kDa 
form, while its truncated version is 57 kDa (Cao et al., 2007; Otera et 
al., 2005). Featuring a strong and positive electrostatic potential on 
its surface as revealed by its solved crystal structures (Mate et al., 
2002; Ye et al., 2002), AIF has three domains with distinct 
functional roles: one on the N terminus that binds flavine-adenine 
dinucleotide (FAD), another in the centre that binds reduced NAD 
(NADH), which governs its oxidoreductase activity, and a third, on 
the C terminus, that underpins its ability to participate in cell 
death (Susin et al., 1999). It exists in multiple isoforms in humans 
(Delettre et al., 2006a; Delettre et al., 2006b; Lorenzo et al., 2007) and 
its oxidoreductase activity is not needed for induction of cell death 
(Ye et al., 2002). 
As with PARP, AIF performs physiological roles when resident 
in its native domain, the intermembrane space of the mitochondria 
(Susin et al., 1999), although there is recent evidence that a small 
proportion may also be found in the outer mitochondrial 
membrane (Yu et al., 2009). The use of the harlequin (Hq) mice in 
which AIF is down-regulated as much as 80% (Klein et al., 2002) 
has revealed that, when in its “ordained” environment, AIF 
supports cell survival, among other possible roles, by mopping up 
reactive oxygen species (ROS), as evidence was found in these 
mice of significant oxidative stress and the progressive 
degeneration of neurones terminally differentiated in the 
cerebellum and retina (Klein et al., 2002).  
The culpability of AIF stems from its translocation from the 
mitochondria to the nucleus, which occurs at the instance of the 
excessive levels of PAR produced following cellular or tissue 
damage. Although PARP-1 as the factory for PAR production does 
not exit the nucleus, its product (PAR) can make a nuclear exit, 
travelling as far as possible (to the cytosol) to signal, in a manner 
that remains to be fully resolved, to the AIF in the mitochondria 
and thus more or less “forcing” it to translocate into the nucleus 
(Andrabi et al., 2008). The appearance of AIF in the nucleus leads to 
large-scale DNA fragmentation and chromatin condensation, 
ultimately precipitating death (Yu et al., 2002). It is now evident 
that the event of nuclear AIF translocation represents a point of no 
return for an injured neurone, beyond which recovery or rescue is 
highly unlikely (Dawson et al., 2004; Hong et al., 2004; Wang et al., 
2003). Furthermore, PAR polymer is now considered a definitive 
signalling molecule bridging the initial process of PARP-1 
overactivation and the succeeding event of AIF translocation, with 
studies having demonstrated that direct exposure of neurones to 
PAR, even exogenously, can induce AIF translocation, and that 
toxicity resulting from the exposure correlates positively with the 
dose and complexity of the polymer (Andrabi et al., 2006; Yu et al., 
2006). However, how AIF causes neuronal death following a 
successful nuclear entry remains to be unequivocally resolved. 
Possible mechanisms include its binding to the DNA, its 
recruitment of endogenous proteases or nucleases such as 
cyclophilin A and endonuclease G (EndoG) (as AIF itself has no 
intrinsic endonuclease activity) (Cande et al., 2004; Irvine et al., 
2005; Wang et al., 2002; Zhu et al., 2007a), or its mediation of DNA 
vulnerability to such molecules through its interactions with the 
DNA. 
BEYOND APOPTOSIS-INDUCING FACTOR: 
PARTNERS IN CONSPIRACY 
As might be suspected, there is now growing evidence of the 
importance of protein-protein interactions in the dissemination of 
PARP-1-mediated neuronal death. PARP-1 itself is known to 
regulate a myriad of proteins and transcription factors, including 
chemokines, cytokines, induced nitric oxide synthase (iNOS), 
nuclear factor kappa-B (NF-kB) and signal transducer and 
activator of transcription-1 (STAT-1) (Kraus et al., 2003; Peralta-
Leal et al., 2009). Likewise, the PAR polymer interacts with several 
proteins, especially those associated with cell death, such as p53 
and caspases (Pleschke et al., 2000; Vaziri et al., 1997). In fact, AIF 
itself has been shown to be a PAR-binding protein through SDS-
PAGE analysis, following immunoprecipitation with anti-PAR 
antibodies, of PAR-associated proteins from PARG-silenced SK-N-
SH cells treated with MNNG, with proteins identified through 
liquid-chromatography tandem mass spectrometry (LC-MS/MS) 
(Gagne et al., 2008).  
Drawing from the aforementioned, one of the lingering 
conundrums to date is whether a number of downstream effectors 
are responsible for linking PAR signalling with AIF release or AIF-
mediated neuronal death. In this context, some proteins, 
mitochondrial or otherwise, have been implicated to interact with 
AIF at various signalling levels, with potential consequences for 
PARP-1-dependent neuronal death, and they include the Bcl-2 
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proteins, calpains, cathepsins, and heat-shock protein 70 (HSP70) 
(Bano et al., 2005; Cao et al., 2007; Cheung et al., 2005; Moubarak et 
al., 2007; Polster et al., 2005; Vosler et al., 2009; Wang et al., 2009b) 
(Chaitanya et al., 2008; Gurbuxani et al., 2003; Ravagnan et al., 2001), 
but for most of these molecules there is yet paucity of evidence, or 
there is conflicting evidence so far, to argue their definitive or 
direct involvement in AIF release, although such potential 
influence(s), if confirmed, may complicate the untangling of the 
entire pathological profile of PARP-1-mediated neuronal death. 
SOME MODELS FOR THE STUDY OF PARP-1-
DEPENDENT CELL (NEURONAL) DEATH 
A number of experimental conditions have been shown to 
reproduce features of PARP-1-mediated cell death and are therefore 
currently being employed to study its mechanistic details and also 
as basis for screening assays for the identification of small 
molecules that could intercept the pathway. In cell lines such as 
HeLa and CHO, or in mouse or human embryonic fibroblasts, the 
DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG) induces PARP-1-dependent cell death in a highly-specific 
and reproducible fashion, and this effect could be blocked 
significantly, if not completely, by PARP-1 inhibitors, but not by 
caspase inhibitors (David et al., 2006; Ethier et al., 2007; Keil et al., 
2006; Yu et al., 2002). Figure 2 illustrates the nuclear translocation 
of AIF in MNNG-treated wild-type fibroblasts and the inability of 
AIF to translocate in fibroblasts treated with MNNG in the 
presence of the PARP-1 inhibitor DPQ or in fibroblasts from PARP-
1 knockout animals treated with MNNG. 
For examination of the cell death pathway in a neuronal 
context, stimuli that can induce toxicity in primary dissociated 
neuronal cultures, such as N-methyl-D-aspartate (NMDA), an 
agonist acting at the NMDA receptor (one of the three ionotropic 
glutamate receptors), or exposure of neurones to ischaemic, 
hypoxic or hypoglycaemic conditions, are able to induce the 
activation of PARP-1 through overactivation of the NMDA 
receptor leading to PARP-1-dependent cell death following a 
number of downstream steps, including excessive rise in calcium 
levels within the cell that activates many calcium-dependent 
processes and enzymes, including neuronal nitric oxide synthase 
(nNOS) that causes nitric oxide (NO) release, which may be 
followed by the reaction of NO with superoxide to produce the 
highly-toxic peroxynitrite that induces significant DNA damage 
(Fatokun et al., 2008; Pacher et al., 2008; Stone et al., 2002; Zhang et 
al., 1994). NMDA and PAR polymer were found to be less toxic to 
neurones from the Hq mice (which have 80% downregulation of 
AIF) and restoration of AIF expression in these neurones increased 
their vulnerability to NMDA-induced cell death to levels found in 
wild-type neurones (Yu et al., 2006). Consistent with these 
observations, the Hq mice also displayed reduced lesions, 
compared to wild-type animals, in experimental models of 
excitotoxicity and stroke (Culmsee et al., 2005; Yuan et al., 2009; 
Zhu et al., 2007b). Apart from exposures involving receptor 
activation, challenging neurones directly with reactive species 
producing oxidative stress (e.g., hydrogen peroxide) or nitrosative 
stress (e.g., nitric oxide, peroxynitrite) can also induce DNA 
damage and lead to PARP-1-mediated neuronal death (Fatokun et 
al., 2007; Fatokun et al., 2008). However, in order to minimise 
FIGURE 2 Nuclear translocation of AIF is PARP-1-dependent. Left Panel: Confocal microscopy demonstrates the translocation of AIF into the 
nucleus following treatment of wild-type (WT) immortalised mouse embryonic fibroblasts with the DNA-alkylating agent, MNNG (0.5 mM, 15 min), 
which induces DNA damage and robustly activates PARP-1. Entrance of AIF into the nucleus is evidenced by the pink overlay of the AIF staining (red) 
and the nuclear staining (blue), 8 h or 24 h after exposure of the cells to MNNG. Middle panel: The PARP-1 blocker DPQ (30 µM) prevents nuclear 
translocation of AIF following exposure of the cells to MNNG, demonstrating that the translocation is PARP-1-dependent. Right panel: Nuclear AIF 
translocation following exposure to MNNG is prevented in PARP-1 knockout (PARP-1 KO) fibroblasts, demonstrating that PARP-1 expression is 
required for PARP-1 activation that induces AIF translocation. Figure reproduced from (Yu et al., 2002) by permission from the American Association for 
the Advancement of Science (AAAS). 
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potential contributions from the other forms of cell death, 
experimental variables such as concentration of the toxic stimulus 
and duration of exposure to it should be optimised in order to 
favour the induction of PARP-1-mediated cell death.  
It should be noted that whole-animal models of neurological 
conditions and neurodegenerative diseases and even post-mortem 
investigations have also been adopted to study PARP-1-mediated 
cell death, with pharmacological or genetic interventions against 
PARP-1 reported to be protective in studies that examined them 
(Komjati et al., 2005; Moroni et al., 2009; Oh et al., 2006; Slemmer et 
al., 2008; Wang et al., 2003; Yu et al., 2010). Recently, a protein, 
named “Iduna”, shown to be a PAR-dependent E3 ubiquitin ligase 
(Kang et al., 2011), was described as the first known endogenous 
inhibitor of PARP-1-mediated cell death (parthanatos) (Andrabi et 
al., 2011). Mechanistically, the protective effects of “Iduna” are due 
to its ability to bind PAR and are thus independent and 
downstream of PARP-1 activity (Andrabi et al., 2011). 
OPPORTUNITIES FOR THERAPEUTIC 
INTERVENTION: BLOCKERS OF NUCLEAR AIF 
TRANSLOCATION AS NOVEL THERAPEUTIC 
AGENTS 
It is now firmly established that PARP-1-mediated cell death is 
unique and distinguishable from other forms of cell death, with 
nuclear AIF translocation representing a key signature step in the 
progression from injury to death. The pathway, as explained 
earlier, seems capable of lending itself to potential therapeutic, and 
perhaps other, interventions at various levels of the cascade (see 
Figure 3). Accordingly, attempts have been made to identify 
chemical molecules that can prevent or, at least, attenuate this cell 
death, most especially at the level of PARP activation (Gero et al., 
2008; Virag et al., 2002), and, as a consequence, there are now series 
of PARP blockers with varying potencies belonging to different 
chemical classes and/or generations in drug development. Some 
have been tested in clinical trials (e.g., INO-1001 (Inotek) for 
myocardial ischaemia) (Lorenzo et al., 2007), but most are still at 
the experimental stage. Examples of first-generation PARP 
blockers are nicotinamide, benzamide and 3-aminobenzamide (3-
AB). Second- and third-generation blockers with improved 
properties (e.g., DPQ and PJ34, respectively) belong to a wide array 
of chemical classes (Eltze et al., 2008; Peralta-Leal et al., 2009) and 
some entered clinical trials, although in most cases not for the 
prevention, but for the promotion, of cell death (in cancer) (see 
(Rouleau et al., 2010)). This is because the inhibition of PARP-1 in 
cancer cells will prevent the activation of PARP-dependent DNA 
damage repair mechanisms in these cells and thus facilitate their 
death. Interestingly, the broad-spectrum tetracycline antibiotic, 
minocycline, was found to inhibit PARP activity at nanomolar 
concentrations (Alano et al., 2006). 
While the development of PARP inhibitors represents a 
rational drug-design approach, the identification of chemical 
entities that can prevent the nuclear translocation of AIF may, in a 
sense, represent a better therapeutic strategy, especially in relation 
to achieving the therapeutic goal of preventing neuronal death in 
neurological and neurodegenerative conditions. Although it may be 
daunting to be able to find molecules that will act with such 
surgical specificity, the fact that PARP has a physiological role that 
should be maintained makes it more desirable to block nuclear AIF 
translocation (and leave PARP alone to do its beneficial work) that 
occurs further downstream, rather than block PARP activation, as 
the latter, if prolonged, could be detrimental to the health of the 
cells (neurones) that are being rescued. It could therefore mean 
that PARP blockade may be more relevant to chemotherapeutics, 
FIGURE 3 Cartoon depicting PARP-1-dependent cell death 
cascade. Exposure of a cell to a toxic stimulus that induces DNA 
damage causes pathological activation of PARP-1, which then 
produces excessive levels of PAR polymer that may overwhelm the 
ability of PARG to hydrolyse it. PAR can attach itself to acceptor 
proteins or to PARP and, once produced in the nucleus, can exit into 
the cytosol, from where it can signal to AIF in the mitochondria. AIF 
is released and translocates to the nucleus, precipitating chromatin 
condensation and large-scale (50 kb) fragmentation of the DNA, 
thus resulting in cell death. Figure reproduced from (Andrabi et al., 
2008) by permission from John Wiley and Sons. 
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where inhibitors can prevent DNA repair in cancerous cells and 
thus promote their death. Interactions of AIF with other proteins 
as it travels from the mitochondria to the nucleus can also be 
targeted, but this will only be possible after its network of 
interacting proteins has been sufficiently clarified.  
Drug discovery efforts in this direction will undoubtedly 
involve experimental, computational and other approaches, with 
the availability of the crystal structure(s) of AIF primed to 
significantly aid computational modelling. Collaborations will 
span various disciplines or technological platforms, including 
biochemistry, molecular biology, pharmacology, medicinal 
chemistry, computational biology and drug discovery. In general, 
there is no denying the fact that latest trends in tackling biological 
targets for therapeutic benefit have confirmed or are confirming 
that the walls that have separated the disciplines for so long are 
fast tumbling down, and wisdom demands that we embrace the 
“holistic” approach to bench-to-bedside drug discovery that will 
occupy the central stage in the 21st century and even well beyond! 
SUMMARY 
This work examines succinctly a distinct form of cell death, 
mediated by overactivation of the nuclear enzyme, PARP, which 
has now been implicated in the pathophysiology of neurological 
and neurodegenerative diseases as well as other conditions. The 
review presents an account of the evolution of scientific 
understanding of the molecular events by which the cell death is 
characterised, the associated players in the cascade, and, where 
already clearly-defined, their spatio-temporal interplay. Blockade 
of nuclear AIF translocation is then presented as a more promising 
avenue for therapeutic intervention. Through the exploration, 
attempt is made to illustrate the challenge of finding, as well as 
sufficiently characterising, a credible and “druggable” therapeutic 
target, using a collection of basic biology approaches from different 
disciplines, before a successful drug campaign is launched, with 
the hope of finding novel lead molecules that will then be 
optimised to obtain candidate drugs for testing in clinical settings. 
It is hoped that such drugs will represent a worthy advancement 
over existing ones in their ability to directly combat the underlying 
death of neurones that is the real plague in many neurological and 
neurodegenerative conditions. 
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